Loading
companiesCompany
Avistone Biotechnology
Avistone Biotechnology is a China-based biotechnology company running 5 late-stage cancer trials of PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer.
Also called: Avistone Biotechnology Co., Ltd.
Overview
Avistone Biotechnology, based in Beijing, China, is a biotechnology company. A commercialisation-stage innovative biopharmaceutical company (Chinese name Anvistone, formerly Beijing Puyuan Anvistone) focused on developing precision cancer medicines, with a manufacturing partner in Ningbo. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer. The largest, NCT07538804 (A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer), plans to enrol 294 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Beijing, CN
Scorecard
All companies#257of 1244 companies, score 19
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +8
1 approved, 0 in phase 3, 0 earlier, 1 targets, 17 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2012
ApprovedOral selective MET tyrosine kinase inhibitor
Vebreltinib is a Chinese MET inhibitor approved in 2023 for lung cancers with a MET exon 14 skipping mutation, and the first drug tested in a phase 3 trial for glioblastomas carrying a PTPRZ1-MET fusion.
Similar pages
- TrialAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Shares Apollomics, Vebreltinib.
- TrialA Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Shares Vebreltinib, Non-small-cell lung cancer.
- TrialA Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Shares Vebreltinib, Non-small-cell lung cancer.
- CancerMET exon 14 and MET-amplified non-small-cell lung cancer
Shares Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC., Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI, Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur, Non-small-cell lung cancer.
- CancerEGFR-mutated non-small-cell lung cancer
Shares A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer, Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations, Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive, A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).
cancers
drugs
ApprovedOral selective MET tyrosine kinase inhibitor
companies
trials
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung CancerA Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung CancerAndamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR MutationsEfficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveVebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKIVebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur